Anika Therapeutics (ANIK) Scheduled to Post Quarterly Earnings on Thursday

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) will be issuing its quarterly earnings data before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.30 per share for the quarter. Anika Therapeutics has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company's conference call can do so using this link.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.24). The business had revenue of $41.92 million during the quarter, compared to analysts' expectations of $39.90 million. Anika Therapeutics had a negative net margin of 44.45% and a positive return on equity of 0.94%. During the same quarter in the prior year, the firm earned ($0.06) EPS. On average, analysts expect Anika Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Anika Therapeutics Price Performance

Shares of NASDAQ:ANIK traded down $0.03 during mid-day trading on Thursday, reaching $24.51. 44,293 shares of the company were exchanged, compared to its average volume of 62,424. The firm has a market cap of $357.53 million, a price-to-earnings ratio of -4.67 and a beta of 0.83. Anika Therapeutics has a 1 year low of $18.08 and a 1 year high of $29.11. The firm's 50-day simple moving average is $25.07 and its 200 day simple moving average is $25.78.

Wall Street Analyst Weigh In

Separately, Barrington Research reaffirmed an "outperform" rating and set a $37.00 target price on shares of Anika Therapeutics in a research note on Tuesday.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.